Major depression: emerging therapeutics
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The first effective antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants, were identified 50 years ago, largely through serendipity. These medications were found to improve mood in a little more than half of depressed patients after a few weeks of chronic use. Almost all antidepressants prescribed today were developed through minor modifications of these original antidepressants and, like monoamine oxidase inhibitors and tricyclic antidepressants, act primarily through monoaminergic mechanisms. Although there have been improvements in side‐effect profiles and overdose toxicity, these newer medications have not provided substantial advances in the efficacy and speed of the antidepressant effect for patients. Over the last 2 decades, our understanding of the neurobiology underlying depression has expanded exponentially. Given this expansion, we may be nearing an inflection point in antidepressant drug development, at which useful medicines will be designed through a rational understanding of the biological systems. In this review, we discuss the biological basis and preclinical and clinical evidence for a series of promising classes of antidepressants developed primarily out of a pathophysiologically informed approach. Mt Sinai J Med 75:203–224, 2008. © 2008 Mount Sinai School of Medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Hippocampal volume and depression: a meta-analysis of MRI studies
Videbech, P., & Ravnkilde, B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1957 · Cited by 1,590
Dunn, A. J., & Berridge, C. W. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90012-d · Cited by 1,352
NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159
A cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Cited by
The Role of BDNF on Neural Plasticity in Depression
Yang, T., Nie, Z., Shu, H., Kuang, Y., Chen, X., Cheng, J., Yu, S., & Liu, H. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00082 · Cited by 435
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Zink, M., Vollmayr, B., Gebicke-Haerter, P. J., & Henn, F. A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.09.005 · Cited by 177
The role of zinc in neurodegenerative inflammatory pathways in depression
Szewczyk, B., Kubera, M., & Nowak, G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.010 · Cited by 176
Dietary zinc and iron intake and risk of depression: a meta-analysis
Li, Z., Li, B., Song, X., & Zhang, D. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.02.006 · Cited by 156
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Pathobiological targets of depression
Chopra, K., Kumar, B., & Kuhad, A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.553603 · Cited by 76
Wang, J., Qiao, J., Zhang, Y., Wang, H., Zhu, S., Zhang, H., Hartle, K., Guo, H., Guo, W., He, J., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12792 · Cited by 43
“According to the World Health Organization, depression will soon be second only to cardiac ischemia in disease-related morbidity and mortality (Sen and Sanacora 2008).”
Background
Metadata
- Authors
- Sen, S., & Sanacora, G.
- Venue
- Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Publisher
- Wiley
- Published
- 2008-06
- Volume
- 75
- Issue
- 3
- Pages
- 204-225
- ISSN
- 0027-2507 (ISSN-L)
- 1931-7581
- OpenAlex
- W2025050647
- Cited by
- 47
- References
- 49
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.